{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:30:58Z","timestamp":1791855058156,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013587","name":"Alaska State Council on the Arts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.neuropharm.2022.109325","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T19:47:58Z","timestamp":1668023278000},"page":"109325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Role of mTOR1 signaling in the antidepressant effects of ketamine and the potential of mTORC1 activators as novel antidepressants"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6166-2698","authenticated-orcid":false,"given":"Taro","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109325_bib1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","article-title":"Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics","volume":"66","author":"Abdallah","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.neuropharm.2022.109325_bib2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41386-020-0644-9","article-title":"Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin","volume":"45","author":"Abdallah","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109325_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109325_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jad.2022.01.104","article-title":"mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression","volume":"303","author":"Averill","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109325_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin\u2013receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109325_bib7","doi-asserted-by":"crossref","first-page":"14368","DOI":"10.1073\/pnas.2336098100","article-title":"Time-restricted role for dendritic activation of the mTOR\u2013p70S6K pathway in the induction of late-phase long-term potentiation in the CA1","volume":"100","author":"Cammalleri","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2022.109325_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0092-8674(00)81653-0","article-title":"A transient, neuron-wide form of CREB-mediated long-term facilitation can be stabilized at specific synapses by local protein synthesis","volume":"99","author":"Casadio","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109325_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coph.2003.10.004","article-title":"Neurotrophic effects of antidepressant drugs","volume":"4","author":"Castr\u00e9n","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109325_bib10","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mp.2017.241","article-title":"Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling","volume":"23","author":"Cavalleri","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.pnpbp.2012.08.001","article-title":"Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress","volume":"40","author":"Chandran","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109325_bib12","article-title":"Comments to behavioral tests for antidepressant-like actions of (2R,6R)-hydroxynorketamine by Bonaventura et al","author":"Chang","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0006-3223(01)01083-6","article-title":"Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication","volume":"50","author":"Chen","year":"2001","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib14","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1073\/pnas.91.26.12574","article-title":"RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12\/rapamycin complex","volume":"91","author":"Chiu","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2022.109325_bib15","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2022.109325_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108068","article-title":"Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine mediated actions","volume":"170","author":"Chou","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109325_bib17","first-page":"1","article-title":"A simple role for BDNF in learning and memory?","volume":"3","author":"Cunha","year":"2010","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109325_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/da.22227","article-title":"Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections","volume":"31","author":"Duman","year":"2014","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2022.109325_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2022.109325_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1017\/S1461145711001702","article-title":"mTOR activation is required for the antidepressant effects of mGluR2\/3 blockade","volume":"15","author":"Dwyer","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109325_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib22","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.995802","article-title":"Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1\/eIF4E","volume":"16","author":"Fingar","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.neuropharm.2022.109325_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","article-title":"mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E","volume":"24","author":"Fingar","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2022.109325_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1073\/pnas.1814709116","article-title":"Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine","volume":"116","author":"Fukumoto","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2022.109325_bib25","doi-asserted-by":"crossref","first-page":"8671","DOI":"10.3390\/ijms22168671","article-title":"mTOR knockdown in the infralimbic cortex evokes a depressive-like state in mouse","volume":"22","author":"Garro-Mart\u00ednez","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109325_bib26","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1172\/JCI130808","article-title":"GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions","volume":"130","author":"Gerhard","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2022.109325_bib27","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/s41380-018-0090-9","article-title":"Antidepressants act by inducing autophagy controlled by sphingomyelin-ceramide","volume":"23","author":"Gulbins","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/ern.10.176","article-title":"Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine","volume":"11","author":"Hashimoto","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2022.109325_bib29","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.biopsych.2017.12.007","article-title":"What are the causes for discrepancies of antidepressant actions of (2R,6R)-hydroxynorketamine?","volume":"84","author":"Hashimoto","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1091\/mbc.5.1.105","article-title":"TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast","volume":"5","author":"Helliwell","year":"1994","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.neuropharm.2022.109325_bib32","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/bcp.12845","article-title":"New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs","volume":"82","author":"Ign\u00e1cio","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109325_bib33","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.pnpbp.2011.05.010","article-title":"The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder","volume":"35","author":"Jernigan","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109325_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.559627","article-title":"Ketamine rescues hippocampal reelin expression and synaptic markers in the repeated-corticosterone chronic stress paradigm","volume":"11","author":"Johnston","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109325_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172827","article-title":"Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: convergent mechanisms","volume":"188","author":"Kato","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109325_bib36","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/mp.2017.220","article-title":"BDNF release and signaling are required for the antidepressant actions of GLYX-13","volume":"23","author":"Kato","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib37","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1172\/JCI126859","article-title":"Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation","volume":"129","author":"Kato","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2022.109325_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.270.5233.50","article-title":"PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints","volume":"270","author":"Keith","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109325_bib39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0092-8674(04)00115-1","article-title":"Translational control by MAPK signaling in long-term synaptic plasticity and memory","volume":"116","author":"Kelleher","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109325_bib40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1523\/JNEUROSCI.21-02-00382.2001","article-title":"Serotonin activates S6 kinase in a rapamycin-sensitive manner in Aplysia synaptosomes","volume":"21","author":"Khan","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109325_bib41","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41593-021-00868-8","article-title":"Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation","volume":"24","author":"Kim","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109325_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109325_bib43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1097-2765(03)00114-X","article-title":"GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR","volume":"11","author":"Kim","year":"2003","journal-title":"Mol. Cell."},{"key":"10.1016\/j.neuropharm.2022.109325_bib44","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.neuropharm.2011.08.034","article-title":"Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists","volume":"61","author":"Koike","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109325_bib45","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0092-8674(93)90144-F","article-title":"Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression","volume":"73","author":"Kunz","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109325_bib46","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109325_bib47","doi-asserted-by":"crossref","first-page":"pyu033","DOI":"10.1093\/ijnp\/pyu033","article-title":"BDNF release is required for the behavioral actions of ketamine","volume":"18","author":"Lepack","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109325_bib48","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2016.09.011","article-title":"Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures","volume":"111","author":"Lepack","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109325_bib49","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109325_bib50","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib51","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.biopsych.2011.09.030","article-title":"Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex","volume":"71","author":"Liu","year":"2012","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib52","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/npp.2016.202","article-title":"GLYX-13 produces rapid antidepressant responses with key synaptic and behavioral effects distinct from ketamine","volume":"42","author":"Liu","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109325_bib53","first-page":"1","article-title":"Fluoxetine regulates mTOR signalling in a region-dependent manner in depression-like mice","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109325_bib54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pnpbp.2018.07.022","article-title":"Ketamine promotes rapid and transient activation of AMPA receptor-mediated synaptic transmission in the dorsal raphe nucleus","volume":"88","author":"Llamosas","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109325_bib55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpsychires.2016.07.004","article-title":"Involvement of PI3K\/Akt\/GSK-3\u03b2 and mTOR in the antidepressant-like effect of atorvastatin in mice","volume":"82","author":"Ludka","year":"2016","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109325_bib56","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.neuron.2022.05.027","article-title":"The role of hippocampal KCNQ2 channel in antidepressant actions of ketamine","volume":"110","author":"Ma","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109325_bib57","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.neuropharm.2005.06.006","article-title":"GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator","volume":"49","author":"Moskal","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109325_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1570159X14666160321122703","article-title":"The development of rapastinel (formerly GLYX-13); a rapid acting and long lasting antidepressant","volume":"15","author":"Moskal","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2022.109325_bib59","series-title":"Navitor's Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression","year":"2019"},{"key":"10.1016\/j.neuropharm.2022.109325_bib60","doi-asserted-by":"crossref","first-page":"634","DOI":"10.12688\/f1000research.8236.1","article-title":"In search of the mechanisms of ketamine's antidepressant effects: how robust is the evidence behind the mTor activation hypothesis","volume":"5","author":"Popp","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.neuropharm.2022.109325_bib61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design","volume":"25","author":"Rush","year":"2004","journal-title":"Contr. Clin. Trials"},{"key":"10.1016\/j.neuropharm.2022.109325_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Sabatini","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109325_bib63","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/npp.2016.224","article-title":"Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study","volume":"42","author":"Sanacora","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109325_bib64","doi-asserted-by":"crossref","first-page":"7366","DOI":"10.1523\/JNEUROSCI.1739-04.2004","article-title":"BDNF regulates the translation of a select group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-kinase-dependent pathway during neuronal development","volume":"24","author":"Schratt","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109325_bib65","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1038\/s41598-019-40693-5","article-title":"Discovery of NV-5138, the first selective brain mTORC1 activator","volume":"9","author":"Sengupta","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109325_bib66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12868-017-0357-0","article-title":"Effects of escitalopram and paroxetine on mTORC1 signaling in the rat hippocampus under chronic restraint stress","volume":"18","author":"Seo","year":"2017","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109325_bib67","first-page":"1642","article-title":"Fluoxetine regulates hippocampal synaptic plasticity in CUMS depression rats","volume":"32","author":"Shen","year":"2016","journal-title":"Chin. J. Pathophysiol."},{"key":"10.1016\/j.neuropharm.2022.109325_bib68","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0092-8674(03)01021-3","article-title":"A neuronal isoform of CPEB regulates local protein synthesis and stabilizes synapse-specific long-term facilitation in aplysia","volume":"115","author":"Si","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109325_bib69","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ijnp\/pyx108","article-title":"Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness model: comparison with (R)-ketamine","volume":"21","author":"Shirayama","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109325_bib70","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/mp.2011.171","article-title":"Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology","volume":"17","author":"Stone","year":"2012","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201600268","article-title":"mTORC1 senses stresses: coupling stress to proteostasis","volume":"39","author":"Su","year":"2017","journal-title":"Bioessays"},{"key":"10.1016\/j.neuropharm.2022.109325_bib72","doi-asserted-by":"crossref","first-page":"42818","DOI":"10.1074\/jbc.M103237200","article-title":"Brain-derived neurotrophic factor enhances neuronal translation by activating multiple initiation processes: comparison with the effects of insulin","volume":"276","author":"Takei","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2022.109325_bib73","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1073\/pnas.012605299","article-title":"A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus","volume":"99","author":"Tang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2022.109325_bib74","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/nn1566","article-title":"Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2","volume":"8","author":"Tavazoie","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109325_bib75","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/23982128221081645","article-title":"A systematic review of studies investigating the acute effects of N-methyl-D-aspartate receptor antagonists on behavioural despair in normal animals suggests poor predictive validity","volume":"6","author":"Viktorov","year":"2022","journal-title":"Brain. Neurosci. Adv."},{"key":"10.1016\/j.neuropharm.2022.109325_bib77","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s11064-015-1633-y","article-title":"Pten inhibitor-bpV ameliorates early postnatal propofol exposure-induced memory deficit and impairment of hippocampal LTP","volume":"40","author":"Wang","year":"2015","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2022.109325_bib78","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fpsyt.2019.00287","article-title":"Regulation of tau protein on the antidepressant effects of ketamine in the chronic unpredictable mild stress model","volume":"10","author":"Wen","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib79","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1172\/JCI85033","article-title":"GABA interneurons mediate the rapid antidepressant-like effects of scopolamine","volume":"126","author":"Wohleb","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2022.109325_bib80","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109325_bib81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuropharm.2017.10.008","article-title":"Hippocampal mTOR signaling is required for the antidepressant effects of paroxetine","volume":"128","author":"Xu","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109325_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.112708","article-title":"The antidepressant-like effects of fluvoxamine in mice involve the mTOR signaling in the hippocampus and prefrontal cortex","volume":"285","author":"Xu","year":"2020","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109325_bib83","doi-asserted-by":"crossref","first-page":"16333","DOI":"10.1016\/S0021-9258(17)34012-7","article-title":"rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein","volume":"269","author":"Yamagata","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2022.109325_bib84","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1471-4159.1998.70020572.x","article-title":"Biochemical pathways by which serotonin regulates translation in the nervous system of Aplysia","volume":"70","author":"Yanow","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2022.109325_bib85","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","article-title":"(R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine","volume":"82","author":"Yang","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib86","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-Ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib87","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib88","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"2533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109325_bib89","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40263-018-0492-x","article-title":"Convergent mechanisms underlying rapid antidepressant action","volume":"32","author":"Zanos","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2022.109325_bib90","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","article-title":"A double-blind, placebo-controlled study of memantine in the treatment of major depression","volume":"163","author":"Zarate","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109325_bib91","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13167","article-title":"Akt3 deletion in mice impairs spatial cognition and hippocampal CA1 long long-term potentiation through downregulation of mTOR","volume":"225","author":"Zhang","year":"2019","journal-title":"Acta Physiol."},{"key":"10.1016\/j.neuropharm.2022.109325_bib92","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.neuropharm.2008.08.018","article-title":"A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus","volume":"55","author":"Zhang","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109325_bib93","doi-asserted-by":"crossref","first-page":"12211","DOI":"10.1523\/JNEUROSCI.3321-07.2007","article-title":"Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments","volume":"27","author":"Zhu","year":"2007","journal-title":"J. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822003847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:20:32Z","timestamp":1758439232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822003847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":93,"alternative-id":["S0028390822003847"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109325","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of mTOR1 signaling in the antidepressant effects of ketamine and the potential of mTORC1 activators as novel antidepressants","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109325"}}